predicting long-term benefit from icis in muc
Published 3 years ago • 24 plays • Length 5:01Download video MP4
Download video MP3
Similar videos
-
1:02
challenges in identifying predictive markers to icis in triple-negative breast cancer
-
3:03
immune-related adverse events in breast cancer patients taking icis
-
2:16
landscape analysis of neoepitope-specific t-cell responses depending on clinical benefit from icis
-
1:53
factors impacting response to icis in muc
-
11:25
icos_ stimulating the immune system for superior cancer therapy
-
1:00:55
the next wave of immunotherapy and cancer treatments | milken institute global conference 2024
-
54:34
cancer immunotherapy: 2022 research and a look ahead with e. john wherry, ph.d.
-
4:56
imeta | tiger: tumor immunotherapy gene expression data analysis r package
-
1:07
checkpoint inhibitors for lung cancer: combating resistance
-
27:43
targeting the immune system with checkpoint inhibitors
-
13:33
technical talk: predicting immune checkpoint inhibitor pneumonitis in lung cancer patients using ...
-
41:34
“challenges and opportunities for machine learning in cancer immunotherapy"
-
25:23
targeting tumor mutations for personalized cancer immunotherapy
-
42:53
biomarkers in cancer immunotherapy: how much do they matter?
-
1:33:59
revisiting pd-l1 as an immunotherapy biomarker across the cancer spectrum
-
1:46
predicting response to checkpoint inhibitors and overcoming resistance in lung cancers
-
2:34
biomarkers of response to checkpoint inhibitors in untreated mnsclc
-
2:20
quantifying the anemia benefit of momelotinib in mf: analysis of data from simplify-1 & simplify-2
-
58:49
curing metastatic solid tumours with immune checkpoint inhibitors by professor james larkin
-
1:03:26
immunotherapy: cure for metastatic cancers? - james larkin
-
0:38
making neuroendocrine tumors more susceptible to immune checkpoint inhibitors
-
37:26
cancer immunotherapy basics: understand the science behind this cutting-edge treatment